Pfizer Inc. Stock
€21.28
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 0.050% | 0.805% | -4.144% | -16.121% | -16.121% | -55.556% | -29.653% |
| Elanco Animal Health Inc. | 2.290% | 2.558% | -3.587% | 67.354% | 67.354% | 70.966% | -22.927% |
| Johnson & Johnson | 0.060% | 1.272% | -0.819% | 27.078% | 27.078% | 6.714% | 40.092% |
| Biogen Inc. | -2.460% | 1.045% | -4.402% | 4.026% | 4.026% | -41.499% | -24.645% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.
Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.
Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.
Comments
News
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026?
The past five years have been challenging for Bristol Myers Squibb (NYSE: BMY). The company lost patent exclusivity for some key products, including one that was once its best-selling medicine
3 Drug Stocks to Buy at a Discount
The pharmaceutical industry is highly technical, and significant developments can rapidly transform the sector. For instance, Novo Nordisk's (NYSE: NVO) introduction of GLP-1 weight loss drugs was a
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?
Shares of Novo Nordisk (NYSE: NVO) surged after the company introduced its GLP-1 weight loss drugs to the market. Investors correctly recognized the desirability of a weight loss drug, but, as often